CMN-005 is under clinical development by CoImmune and currently in Phase II for Mantle Cell Lymphoma.
AstraZeneca champions early kidney disease diagnosis with modelling data – Pharmaceutical Technology
AstraZeneca’s office in Södertälje, Sweden. The company aims to reduce progression to kidney failure by 20% by 2025. Credit: Mats Wiklund via Shutterstock. AstraZeneca has